ROXADUSTAT - a multipronged development strategy
In this whitepaper, we outline how various strategies for the development of Roxadustat resulted in a successful filling of the USDMF in March 2020 to help our partners across geographies provide patients early treatment access.
Roxadustat is a first-in-class small molecule oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and increases the endogenous production of erythropoietin, which stimulates the production of haemoglobin and red blood cells. This innovative approach has ordered a breakthrough in treating patients with anaemia in chronic kidney disease (CKD).
We can address customized particle size distribution requirements through size reduction and crystallization techniques to meet the most desired particle size distributions consistently at a commercial scale.
To know more about our offerings , please read the technical sheet on Roxadustat by filling the contact from below.
Explore other Whitepapers:Know More